What is Imatinib?

Category: Prescription Drugs

Most popular types: Gleevec

false

Imatinib is an antineoplastic agent which inhibits BCR-ABL tyrosine kinase, the abnormal gene product of the Philadelphia chromosome in chronic myeloid leukemia. It is also used for Ph+ acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GIST).

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Chronic myeloid leukemia 19 12
Gastrointestinal stromal tumors 8 3
Giant cell tumor of the bone 1 0
Hypereosinophilic syndrome 1 1
Myeloproliferative disorder 1 1

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
2
Moderate
3
Mild
11
None
0

Commonly reported side effects and conditions associated with Imatinib

Side effect Patients
Diarrhea 6
Nausea 3
Fatigue 2
Chronic diarrhea 1
Chronic fatigue 1
Damage to teeth 1

Show all 25 reported side effects

Dosages

Based on patients currently taking Imatinib

Dosage Patients
400 mg daily 5
100 mg daily 1
200 mg daily 1
300 mg daily 1

Why patients stopped taking Imatinib

Multiple reasons could be selected

Reason Patients
Doctor's advice 3
Side effects too severe 3
Did not seem to work 2
Other 1
See all 6 patients who've stopped taking Imatinib

Duration

Currently taking Imatinib

Duration Patients
1 - 6 months 1
1 - 2 years 1
2 - 5 years 3
5 - 10 years 1
10 years or more 2

Stopped taking Imatinib

Duration Patients
Less than 1 month 1
6 months - 1 year 3
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 15
Usually 1
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 4
Not at all hard to take 11
Cost per month
Cost per month Evaluations
$200+ 2
$100-199 1
$50-99 0
$25-49 7
< $25 1
Not specified 5

What people switch to and from

Patients stopped taking Imatinib and switched to:

Treatment Patients
Dasatinib (Sprycel) 1
Sorafenib (Nexavar) 1
Last updated:
There are no evaluations for Imatinib.